NASDAQ
1.20USD
-0.03 (-2.44%)
We have scored 5 news catalysts on Pluri Inc. (PLUR) over the past 12 months. The biggest single-day move next to one of them came Apr 21, 2026, when PLUR closed −6.7%: “Plurilock Announces $2.5 Million Non-Brokered Private Placement”. Coverage across the window leans positive (average ticker sentiment +0.42). Most of the impact sits in short squeeze potential and eps growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
12.9M
P/E
—
EPS
—
Beta
0.69
52W range
0.85-4.87
Day range
1.18–1.23
Open
1.23
Prev close
1.23
Volume
37.4K
Avg volume
35.9K
Dividend
0.00
IPO
2003-06-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Pluri Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PLUR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
